Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

Stephanie M. Cushman1, Chen Jiang2, Ace J. Hatch1, Ivo Shterev2, Alexander B. Sibley2, Donna Niedzwiecki2, Alan P. Venook3, Kouros Owzar2, Herbert I. Hurwitz1, and Andrew B. Nixon1

Abstract

Purpose: Formalin-fixed, paraffin-embedded tumor samples from CALGB 80203 were analyzed for expression of EGFR axis-related genes to identify prognostic or predictive biomarkers for cetuximab treatment.

Patients and Methods: Patients (238 total) with first-line metastatic colorectal cancer (mCRC) were randomized to FOLFOX or FOLFIRI chemotherapy ± cetuximab. qRT-PCR analyses were conducted on tissues from 103 patients at baseline to measure gene expression levels of HER-related genes, including amphiregulin (AREG), betacellulin (BTC), NT5E (CD73), DUSP4, EGF, EGFR, epigen (EPGN), epiregulin (EREG), HBEGF, ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4), PHLD1A, and TGFα. The interactions between expression levels and treatment with respect to progression-free survival (PFS) and overall survival (OS) were modeled using multiplicative Cox proportional hazards models.

Results: High tumor mRNA levels of HER2 [hazard ratio (HR), 0.64; \( P = 0.002 \)] and EREG [HR, 0.89; \( P = 0.016 \)] were prognostic markers associated with longer PFS across all patients. HER3 and CD73 expression levels were identified as potential predictive markers of benefit from cetuximab. In KRAS wild-type (WT) tumors, low HER3 expression was associated with longer OS from cetuximab treatment, whereas high HER3 expression was associated with shorter OS from cetuximab treatment (chemo + cetuximab: HR, 1.15; chemo-only: HR, 0.48; \( P_{\text{interaction}} = 0.029 \)). High CD73 expression was associated with longer PFS from cetuximab treatment in patients with KRAS-WT (chemo + cetuximab: HR, 0.91; chemo-only: HR, 1.57; \( P_{\text{interaction}} = 0.026 \)) and KRAS-mutant (Mut) tumors (chemo + cetuximab: HR, 0.80; chemo-only: HR, 1.29; \( P = 0.025 \)).

Conclusions: Gene expression of HER3 and CD73 was identified as a potential predictive marker for cetuximab. These data implicate HER axis signaling and immune modulation as potential mechanisms of cetuximab action and sensitivity. Clin Cancer Res; 1–9. ©2014 AACR.

Introduction

Epidermal growth factor receptor (EGFR)-targeted therapies have shown clinical benefit in the treatment of numerous cancers, including metastatic colorectal cancer (mCRC; ref 1). Cetuximab, a chimeric monoclonal anti-EGFR antibody, is FDA and EMA approved for use in combination with FOLFIRI chemotherapy in the first-line setting and as monotherapy or with irinotecan in late-line treatment of KRAS wild-type (WT) mCRC. Recent data also suggest the activity of cetuximab with FOLFOX-based chemotherapy (2).

EGFR is a member of the ERBB/HER family of receptor tyrosine kinases (RTK). Ligand binding causes homo- and hetero-dimerization between EGFR and the other members of the HER family (ERBB2/HER2, ERBB4/HER4), and the kinase-inactive ERBB3/HER3) resulting in downstream activation of the RAS-RAF-MEK and PI3K-AKT pathways (3). Multiple strategies have been developed for the therapeutic inhibition of EGFR signaling pathways and significant effort has been devoted to identifying biomarkers that can predict those patients most and least likely to benefit from EGFR-targeted therapies. Currently, only RAS mutation status has been validated as a predictive marker for anti-EGFR antibodies (4, 5). Activating RAS mutations occur downstream from the RTK EGFR, providing proliferative signals independent of EGFR ligand binding, and cause resistance to EGFR blockade (6, 7). The initial reports showing that mutations in KRAS conferred resistance to EGFR-targeting therapies focused on mutations in codons 12 and 13 of exon 2 (4, 8). Recent studies have identified mutations in exon 3 and 4 of KRAS and exons 2, 3, and 4 of NRAS as additional markers of resistance to anti-EGFR antibodies in colorectal cancer (9, 10). Intriguingly, gene expression signatures of activated RAS often indicate upregulation of several EGFR ligands and inflammatory mediators (11–13). Moreover, feedback loops

1Duke University Medical Center, Durham, North Carolina. 2Alliance Statistical and Data Center, Durham, North Carolina. 3University of California, San Francisco—Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Current address for S.M. Cushman: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Corresponding Author: Andrew B. Nixon, Duke University Medical Center, 309 MSRB, 203 Research Drive, Box 2631, Durham, NC 27710. Phone: 919-613-7883; Fax: 919-668-3925; E-mail: anixon@duke.edu

doi: 10.1158/1078-0432.CCR-14-2313

©2014 American Association for Cancer Research.
Translational Relevance

Beyond KRAS status, there are no validated biomarkers for anti-EGFR therapy in metastatic colorectal cancer (mCRC). Expression of genes within the EGFR signaling axis has been reported to correlate with benefit, but most reports have used nonrandomized data that cannot distinguish prognostic and predictive markers. This report is one of the first generated from a randomized trial to identify predictive markers of benefit from cetuximab in mCRC. Gene expression of HER3 and CD73 was identified as a potential predictive marker for cetuximab. Although the current sample size is small and the conclusions should be considered preliminary, they implicate both HER axis signaling and immune modulation as potential mechanisms of cetuximab action and sensitivity.

Patients and Methods

Study design and patients

Patients with previously untreated, metastatic adenocarcinoma of the colon or rectum were randomized to FOLFIRI, FOLFIRI + cetuximab, FOLFOX, or FOLFOX + cetuximab treatment groups. This was a multicenter trial; 238 patients were randomized to treatment. Consent for biomarker analyses was optional. The protocol was approved by the Institutional Review Boards at each participating institution. This retrospective analysis conforms to the reporting guidelines established by the REMARK criteria.

Sample collection

Formalin-fixed, paraffin-embedded (FFPE) baseline tumor samples were collected during study enrollment. A total of 110 consenting patients (48%) had at least one paraffin block of primary colon or rectum tumor available for analysis. Seven samples were further excluded from this analysis due to quality and quantity issues related to the RNA isolation (Fig. 1).

KRAS mutational analysis

KRAS mutation status was determined by real-time PCR using the TheraScreen: KRAS Mutation Test Kit from Qiagen-Dxs Diagnostic Innovations, which is able to detect the seven common mutations of the KRAS gene at codons 12 and 13 (G12A, G12D, G12R, G12C, G12S, G12V, and G13D). Analysis was performed in the Alliance molecular reference laboratory of Dr. Greg Tsongalis (Dartmouth Medical School, Hanover, NH).

RNA isolation and qRT-PCR analysis

A hematoxylin and eosin (H&E)-stained image of the tumor sample was reviewed by a pathologist to ensure the presence of >70% tumor tissue within the sample and quality of the tumor. If samples were <70% tumor, macro-dissection was performed manually. FFPE tumor biopsies were cut at the CALGB (Alliance) pathology coordinating office and shipped overnight to the Alliance molecular reference laboratory at Duke University. RNA was isolated from six 10-μm sections using the Ambion RecoverAll Total Nucleic Isolation Kit according to the manufacturer's protocol (Ambion-Life Technologies). RNA (200 ng) from each sample was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems-Life Technologies). TaqMan quantitative PCR was performed for EGFr-related growth factor-α (TGFA), and their receptors (EGFR, HER2, HER3, and HER4). In addition, CD73, DUSP4, and PHLD41 gene expression has been correlated to cetuximab resistance in several single-arm monotherapy studies of colorectal cancer (13, 19); therefore, we also evaluated their utility as prognostic and predictive markers in this study. The closure of CALGB 80203 after partial enrollment limits the power of our retrospective analysis and we wish to emphasize that conclusions should be considered preliminary until they can be verified in larger randomized studies. Although the number of patients is limited, the inclusion of KRAS-mutant (Mut) patients in the cetuximab arms of this study cannot be repeated in the future due to ethical concerns. Therefore, the sample population in CALGB 80203 gives us a unique opportunity to investigate pathways relevant to cetuximab response in KRAS-Mut patients. This is one of the first randomized studies to evaluate predictive gene expression markers of cetuximab efficacy and resistance in first-line treatment of mCRC (21).

Cushman et al.
gene expression (primer-probe sets described in Supplementary Table S1), using the ABI 7900HT Real-Time PCR System (Applied Biosystems-Life Technologies). The log-transformed relative amounts of mRNA expression were normalized to \( \beta \)-actin mRNA and expressed as \( \log_2(C_{T(X)} - C_{T(\beta \text{-actin})}) = C_{T(X)} - C_{T(\beta \text{-actin})} \), where \( C_T \) is the threshold cycle. TaqMan gene expression assays were chosen for each gene to span exon–exon junctions and have small amplicons <100 base pairs to allow for specific and sensitive detection of degraded RNA. Life Technologies TaqMan Gene Expression Assays have amplification efficiencies of approximately 100% (±10%). The \( \beta \)-actin endogenous control was used in this analysis. We observed uniform expression of \( \beta \)-actin across the mCRC tumor samples in this study. The mean \( C_T \) value was 23.6 cycles with a standard deviation of 1.9 cycles across the CALGB 80203 sample population. Duplicate samples with \( C_T \) standard deviation greater than 0.5 cycles were re-run for improved qPCR reproducibility.

### Statistical analysis

Expression levels were normalized relative to \( \beta \)-actin, as described above, and analyzed as continuous measures. A Kendall tau analysis was performed to identify coregulated genes. Univariate Cox (22) regression was used to identify markers prognostic of clinical outcomes (OS and PFS), and the resulting \( P \) values, HRs, and 95% CIs are reported. To identify predictive markers, expression level was correlated with clinical outcomes (OS and PFS) using multiplicative Cox proportional hazards models to test for interaction between genetic expression and treatment (chemo vs. chemo + cetuximab). Visualizations of the resulting effect sizes are provided in the form of forest plots. The forest plots illustrate the HRs of the expression levels (and the corresponding 95% CI) within each treatment group, and the \( P \) values for the tests of interaction are provided. The Kaplan–Meier plots of OS and PFS were generated as additional visualizations of selected predictive markers, with separate curves for each

### Table 1. Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Overall whole population</th>
<th>Overall biomarker population</th>
<th>Chemo-only (biomarker population)</th>
<th>Chemo + cetux (biomarker population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>238 (100)</td>
<td>103 (43)</td>
<td>52 (50.5)</td>
<td>51 (49.5)</td>
</tr>
<tr>
<td>Age, y</td>
<td>Median 61.3</td>
<td>61.1</td>
<td>61.3</td>
<td>60.9</td>
</tr>
<tr>
<td>Range</td>
<td>22–84.4</td>
<td>22–83.3</td>
<td>22–83.2</td>
<td>40.4–83.3</td>
</tr>
<tr>
<td>Gender male</td>
<td>140 (58.9)</td>
<td>57 (55.3)</td>
<td>27 (51.9)</td>
<td>30 (58.8)</td>
</tr>
<tr>
<td>Race white</td>
<td>207 (87.0)</td>
<td>91 (88.3)</td>
<td>45 (86.5)</td>
<td>46 (90.2)</td>
</tr>
<tr>
<td>ECOG PS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>125 (52.5)</td>
<td>51 (49.5)</td>
<td>25 (48.1)</td>
<td>26 (51)</td>
</tr>
<tr>
<td>1</td>
<td>113 (47.5)</td>
<td>52 (50.5)</td>
<td>27 (51.9)</td>
<td>25 (49)</td>
</tr>
<tr>
<td>KRAS-WT</td>
<td>94/165 (57)</td>
<td>55 (53.4)</td>
<td>29 (55.8)</td>
<td>26 (51)</td>
</tr>
<tr>
<td>Median OS (95% CI)</td>
<td>23.0 (20.6–26.1)</td>
<td>26.4 (22.6–32)</td>
<td>22.8 (16.7–33)</td>
<td>27.6 (23.4–38.0)</td>
</tr>
<tr>
<td>Median PFS (95% CI)</td>
<td>11.05 (9.79–13.04)</td>
<td>9.67 (8.05–12.45)</td>
<td>9.66 (8.34–12.6)</td>
<td>10.25 (6.9–15.3)</td>
</tr>
<tr>
<td>Response rate (CR/PR)</td>
<td>104 (43.7)</td>
<td>42 (40.8)</td>
<td>20 (38.5)</td>
<td>22 (43.1)</td>
</tr>
</tbody>
</table>
indicated that of the overall population (Table 1). Although most studies have similar outcomes across the FOLFOX and FOLFIRI treatment rates, PFS and OS (20). Because of the small size of this study and FOLFOX and FOLFIRI treatment groups showed similar response rates, PFS and OS (20). Because of the small size of this study and retrospective nature of this study, results should be considered exploratory and hypothesis-generating in nature. Further validation of predictive markers in other datasets will be necessary before they can be applied prospectively. Data collection and statistical analyses were conducted by the Alliance Statistics and Data Center. All clinical data were locked on March 5, 2012. Statistical analyses and figures were generated using the R software environment for statistical computing and graphics (23) with the survival (22) package.

Results

Patient characteristics
Patients (238) with previously untreated mCRC were enrolled and randomly assigned to one of four treatment groups: FOLFOX, FOLFOX + cetuximab, FOLFIRI, or FOLFIRI + cetuximab. The FOLFOX and FOLFIRI treatment groups showed similar response rates, PFS and OS (20). Because of the small size of this study and similar outcomes across the FOLFOX and FOLFIRI treatment groups, these groups were combined into chemotherapy (chemo) only and chemo + cetuximab cohorts for this analysis. Patient characteristics of the biomarker population were similar to those of the overall population (Table 1). Although most studies have indicated that KRAS exon 2 mutations comprise approximately 40% of the colorectal cancer patient population, the biomarker population in this study had a slightly higher proportion of KRAS-Mut patients (Table 1). Within the biomarker population, the chemo + cetuximab cohort showed longer median PFS and OS times with higher response rates compared with the chemo-only cohort, but these differences were not statistically significant.

FPFE tissue blocks from the primary tumor site (colon or rectum) were processed from 110 patients; however, seven RNA samples were excluded because of RNA quality and quantity issues, leaving 103 patients (43%) to be included in this RNA biomarker analysis (Fig. 1). These patients were evenly distributed within the chemo-only and chemo + cetuximab treatment groups (52 vs. 51 patients). The median follow-up time for all 103 patients included in the biomarker cohort was 69.2 months.

Gene expression in primary tumors
Expression of 14 genes related to the EGF-signaling pathway (AREG, BTC, CD73, DUSP4, EGF, EGFR, EPN, EREG, HBEFG, HER2, HER3, HER4, PHLDA1, and TGFα) was analyzed using TaqMan qRT-PCR from the primary tumors. Most genes were expressed at detectable levels in >90% patients (Supplementary Table S1). Gene expression was most strongly correlated between AREG and AREG (r 0.53), with HER2 and HER3 also showing strong coexpression (r 0.475; Supplementary Table S2). EPN was coexpressed with both HER4 (r 0.500) and EGF (r 0.571), but the low expression levels of these genes may affect interpretation of these results (Supplementary Table S1).

Prognostic gene expression biomarkers
The baseline gene expression levels were tested for association with OS and PFS using Cox proportional hazards
regression modeling. Prognostic univariate Cox regression analyses were conducted across all patients, and within KRAS-WT and KRAS-Mut subgroups. For OS across all patients, none of the assayed genes were identified as statistically significant prognostic markers for OS across all patients (Table 2), but favorable prognostic trends were noted for HER2 (HR, 0.78; 95% CI, 0.60–1.02; \( P = 0.071 \)) and EGF (HR, 0.84; 95% CI, 0.68–1.03; \( P = 0.093 \)). For OS, EREG expression was favorably prognostic for OS in the KRAS-WT group (HR, 0.87; 95% CI, 0.77–0.98; \( P = 0.017 \)). For PFS, HER2 (HR, 0.64; 95% CI, 0.49–0.85; \( P = 0.002 \)) and EREG (HR, 0.89; 95% CI, 0.80–0.98; \( P = 0.016 \)) were favorable prognostic markers across all patients. This effect seems to be driven by the KRAS-WT subgroup. Both HER2 (HR, 0.66; 95% CI, 0.47–0.92; \( P = 0.013 \)) and EREG (HR, 0.84; 95% CI, 0.74–0.96; \( P = 0.008 \)) were significant prognostic markers in the KRAS-WT group, but failed to show significance in the KRAS-Mut group (HER2, \( P = 0.123 \); EREG, \( P = 0.526 \)). The prognostic associations of each assayed gene with OS and PFS are included in Supplementary Figs. S1 and S2.

### Predictive gene expression biomarkers

Cox proportional hazards models of OS and PFS were used to test for interaction between treatment and continuous tissue gene expression, and identified expression of HER3 and CD73 as potential predictive markers for benefit or lack of benefit from cetuximab. Forest plots of the HR of gene expression by treatment group are presented for OS and PFS outcomes. Markers with a \( P_{\text{interaction}} \leq 0.2 \) are shown in Figs. 2 and 3, while a complete analysis showing all markers is included in Supplementary Figs. S3 and S4.

Higher levels of HER3 expression showed evidence of being predictive for lack of benefit from cetuximab, an effect that appeared restricted to the KRAS-WT group. For OS in the KRAS-WT group, the HR for chemo + cetuximab was 1.15 (95% CI, 0.81–1.62) and the HR in the chemo-only group was 0.48 (95% CI, 0.27–0.87; \( P_{\text{interaction}} = 0.029 \); Fig. 2A). However, in the KRAS-Mut population, HER3 was not predictive of either OS or PFS benefit from cetuximab (Figs. 2B and 3B).

Gene expression of CD73 showed a similar trend toward predicting for OS benefit from cetuximab in the KRAS-WT (\( P_{\text{interaction}} = 0.14 \)) and KRAS-Mut (\( P_{\text{interaction}} = 0.092 \)) groups. Higher levels of CD73 expression predict for PFS benefit from cetuximab, an effect that appeared to be consistent in both KRAS-WT and KRAS-Mut groups. For PFS in the KRAS-WT group, the HR was 0.91 (95% CI, 0.70–1.18) for the chemo + cetuximab group and 1.57 (95% CI, 1.11–2.23) for the chemo-only group (\( P_{\text{interaction}} = 0.026 \)). For PFS in the KRAS-Mut group, the HR was 0.80 (95% CI, 0.60–1.07) for the chemo + cetuximab and 1.29 (95% CI, 0.91–1.83) for the chemo-only group (\( P_{\text{interaction}} = 0.025 \)). The Kaplan–Meier plots of high and low expression of HER3 and CD73 (dichotomized at the median) are also shown (Fig. 4).

### Discussion

To date, the search for predictive markers for anti-EGFR therapies has focused largely on driver mutations, such as KRAS, NRAS, RAF, and PI3K. However, the importance of nonmutated factors in the HER axis is supported by several preclinical and clinical reports (18, 21, 24). For these reasons, we undertook an analysis of gene expression of all HER axis ligands and receptors, as well as other top candidates that had been previously identified (19).

Our analysis of CALGB 80203 is one the largest analyses of gene expression in a first-line mCRC study to date and focused exclusively on defined candidates previously reported in the literature with known biologic relevance to the EGFR axis. A key advantage of CALGB 80203 for biomarker analyses is its use of randomization between chemotherapy with and without cetuximab. Without randomization, the prognostic and predictive roles of candidate markers cannot be distinguished and their roles may be confounded or obscured. Nevertheless, our results should be considered exploratory due to the limited sample size of the study, the number of markers analyzed, and the potential for higher order interactions between markers, between markers and KRAS status, and with FOLFIRI versus FOLFOX treatment.

Despite these limitations, our findings suggest both the HER axis and inflammatory pathways mediate resistance to cetuximab.

---

**Figure 2.**

Forest plots showing the associations of gene expression and treatment group with OS in KRAS-WT (A) and KRAS-Mut (B) patients. Only genes with \( P_{\text{interaction}} \leq 0.2 \) are shown. The length of the line indicates the 95% CI and the diameter of the median dot is inversely proportional to the standard deviation.

---

**Table 2.**

<table>
<thead>
<tr>
<th>Gene</th>
<th>OS HR (95% CI)</th>
<th>P value</th>
<th></th>
<th>PFS HR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EREG</td>
<td>0.87 (0.77–0.98)</td>
<td>0.017</td>
<td></td>
<td>0.89 (0.80–0.98)</td>
<td>0.016</td>
</tr>
<tr>
<td>HER3</td>
<td>1.15 (0.81–1.62)</td>
<td>0.013</td>
<td></td>
<td>0.48 (0.27–0.87)</td>
<td>0.029</td>
</tr>
</tbody>
</table>

---

**Supplementary Figures.**

S1 and S2 show additional details on prognostic and predictive roles of candidates previously identified (19).
High HER3 levels were associated with both resistance and lack of benefit from cetuximab. This effect was most prominent in patients whose tumors were KRAS-WT. Expression of other markers in the HER axis showed a trend for predicting benefit from cetuximab. Her3 is kinase-deficient, but it heterodimerizes with Her2 to generate a potent signaling module. Her2 and Her3 are also activated by EGF and BTC providing additional means for these ligands to support cell signaling and growth (26). Although signaling through Her3 has been shown to confer resistance to anti-EGFR agents in preclinical models (27, 28), evidence for this signaling through Her3 has been shown to confer resistance to anti-EGFR therapies. Intriguingly, cetuximab induces an acneiform rash, which is predominantly neutrophilic and responds to anti-inflammatory agents, such as minocycline and steroids (38, 39). Whether similar infiltrates are also induced in the tumor microenvironment in patients is not known but is highly plausible. In this context, our CD73 data suggest potentially important roles for inflammation and immunity as mechanisms of sensitivity and resistance to cetuximab treatment. The predictive role for CD73 in patients whose tumors are KRAS-Mut suggests that inflammation could be an additional mechanism of RAS-mediated resistance to cetuximab. Many immune subpopulations, particularly those mediating inflammation, can exert a negative effect on antitumor immunity, including cell types regulated by CD73 such as neutrophils, Tie2-expressing macrophages, and Tregs (40–45).

Macrodissection enriched the tumor content for each sample, but this still represents a complex mixture of both tumor and the surrounding stroma. The expression patterns we have observed may not be intrinsic to the tumor only. In fact, these samples represent a baseline snapshot of expression that may reflect complex signaling between the tumor and its environment. Further studies are required to evaluate changes in mRNA expression associated with either cetuximab treatment or the progression of the disease.

Our results serve to extend and refine many of the findings initially reported by Baker and colleagues (19). However, our results also differ somewhat from the results of those studies. These differences may relate to numerous factors, including potential differences in study populations, preanalytic considerations, which analytes were measured, and whether the studies were or were not randomized. A major strength of the current analysis is the randomization used in the parent study. In a recent study...
In conclusion, using samples from the randomized CALGB 80203 study in first-line mCRC, we identified two strong potential candidate predictors of benefit from cetuximab, HER3 and CD73. These data implicate specific and targetable factors in the HER axis and inflammation as key mediators of resistance to cetuximab.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Authors’ Contributions**

Conception and design: S.M. Cushman, D. Niedzwiecki, K. Owzar, H.I. Hurwitz, A.B. Nixon

Development of methodology: S.M. Cushman, K. Owzar, H.I. Hurwitz, A.B. Nixon

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.M. Cushman, H.I. Hurwitz

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.M. Cushman, C. Jiang, A.J. Hatch, I. Shterev, A.B. Sibley, A.P. Venook, K. Owzar, H.I. Hurwitz, A.B. Nixon

Writing, review, and/or revision of the manuscript: S.M. Cushman, A.J. Hatch, A.B. Sibley, D. Niedzwiecki, A.P. Venook, K. Owzar, H.I. Hurwitz, A.B. Nixon

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.M. Cushman, K. Owzar

Study supervision: A.P. Venook, A.B. Nixon

Other (lead statistician of the study): K. Owzar

**Disclaimer**

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

The combination of KRAS status plus EREG was found to be a significant predictor of benefit from cetuximab, although EREG alone was of only borderline significance (21). Other candidate markers beyond EREG were not reported in that analysis.

In conclusion, using samples from the randomized CALGB 80203 study in first-line mCRC, we identified two strong potential candidate predictors of benefit from cetuximab, HER3 and CD73. These data implicate specific and targetable factors in the HER axis and inflammation as key mediators of resistance to cetuximab.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Authors’ Contributions**

Conception and design: S.M. Cushman, D. Niedzwiecki, K. Owzar, H.I. Hurwitz, A.B. Nixon

Development of methodology: S.M. Cushman, K. Owzar, H.I. Hurwitz, A.B. Nixon

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.M. Cushman, H.I. Hurwitz

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.M. Cushman, C. Jiang, A.J. Hatch, I. Shterev, A.B. Sibley, A.P. Venook, K. Owzar, H.I. Hurwitz, A.B. Nixon

Writing, review, and/or revision of the manuscript: S.M. Cushman, A.J. Hatch, A.B. Sibley, D. Niedzwiecki, A.P. Venook, K. Owzar, H.I. Hurwitz, A.B. Nixon

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.M. Cushman, K. Owzar

Study supervision: A.P. Venook, A.B. Nixon

Other (lead statistician of the study): K. Owzar

**Disclaimer**

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.

**Disclosure of Potential Conflicts of Interest**

S.M. Cushman is an employee of Novartis Pharmaceutical Corporation. A.P. Venook is a consultant/advisory board member for Merck Serono. H.I. Hurwitz reports receiving commercial grants from Bristol-Myers Squibb, Genentech/Roche, and Lilly and is a consultant/advisory board member for Bristol-Myers Squibb, Genentech/Roche, Incyte, Lilly, Regeneron, and Sanofi. A.B. Nixon reports receiving commercial grants from Amgen, Pfizer, and Tracor Pharmaceuticals and is a consultant/advisory board member for GlaxoSmithKline and Novartis. No potential conflicts of interest were disclosed by the other authors.

**Acknowledgments**

The authors gratefully acknowledge the invaluable contributions of the patients, their families, and all the investigators who participated in this trial. The authors give special recognition to Dr. Greg Tsongalis (Dartmouth Medical School) for providing the mutational data.
CA4811; University of Iowa, Iowa City, Iowa; Daniel A. Vaena, supported by CA47642; University of Massachusetts Medical School, Worcester, MA; William W. Walsh, supported by CA37135; University of Minnesota, Minneapolis, Minnesota; Bruce A. Peterson, supported by CA16450; University of Nebraska Medical Center, Omaha, Nebraska, Apar Ganti, supported by CA77298; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, Thomas C. Shea, supported by CA47559; Wake Forest University School of Medicine, Winston-Salem, North Carolina, David D. Hund, supported by CA93927; Walter Reed Army Medical Center, Washington, DC; David C. Van Echo, supported by CA26806; Washington University School of Medicine, St. Louis, Missouri, Nancy Bartlett, supported by CA77440; Weill Medical College of Cornell University, New York, New York, John Leonard, supported by CA67964.

Cushman et al.

References

2. Venook AP, Niedzwiecki D, Lenz HI, Innocenti F, Mahoney M, O’Neil BH, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2013;31:5s, 2013 (suppl; abstr 3B33).
10. Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2009;27:5068–74.
20. Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2009;27:5068–74.

Grant Support

Research reported in this publication was supported by the National Cancer Institute of the NIH under award numbers HULCA118821, U10CA188082, CA31946, CA31601, CA47577, and CA60138.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 10, 2014; revised November 4, 2014; accepted December 4, 2014; published OnlineFirst December 17, 2014.

OF8: Clinical Cancer Res; 2015


Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

Stephanie M. Cushman, Chen Jiang, Ace J. Hatch, et al.

Clin Cancer Res  Published OnlineFirst December 17, 2014.